Background. Chronic obstructive pulmonary disease (COPD) exacerbation and community-acquired pneumonia (CAP) are major drivers of antibiotic overuse, primarily due to challenges in pathogen identification. Procalcitonin is a serum biomarker that assists in distinguishing bacterial infection from other causes. The purpose of this study was to determine whether the use of a procalcitonin (PCT) guided algorithm in patients diagnosed with COPD exacerbation and/or CAP can reduce antibiotic exposure without negatively impacting clinical outcomes.

Methods. This was a quasi-experimental study conducted at Mercy Medical Center in Canton, Ohio. The patient data for the retrospective cohort (control group) was collected from the months of September 2017 through January 2018. The prospective phase (PCT group) took place during the months of September 2018 through January 2019. Physicians utilized a procalcitonin guided algorithm to determine appropriate initiation and duration of antibiotic use in patients admitted with a primary diagnosis of COPD exacerbation and/or CAP. The primary outcome was the duration of antibiotic therapy, measured in days. Secondary outcomes included all-cause hospital readmission within 30 days of discharge, respiratory-related hospital readmission within 30 days of discharge, 30-day mortality, hospital length of stay, and adverse events to antibiotics.

Results. A total of 76 patients were included in the study, 43 in the control group and 33 in the PCT group. Baseline characteristics were similar between groups. The use of a PCT algorithm significantly decreased duration of antibiotics by 2.7 days in comparison to the control group (2.6 [$n = 33$] vs. 5.3 [$n = 43$] days; $P < 0.001$; 95% CI). Secondary safety outcomes between the PCT and control group were similar, including all-cause hospital readmission within 30 days of discharge (30.3% vs. 25.6%; $P = 0.648$), respiratory-related hospital readmission within 30 days of discharge (80.0% [$n = 10$] vs. 81.8% [$n = 11$]; $P = 0.731$), and 30-day mortality (no incidence in either group).

Conclusion. The use of a PCT algorithm significantly reduced duration of antibiotics by 2.7 days without negatively impacting clinical outcomes in patients being treated for COPD exacerbation and/or CAP.

Length of Antibiotic Therapy

95% CI (p<0.001)

Control (n=43): 5.3 (3.51)
PCT (n=33): 2.6 (2.55)

Mean Antibiotic Days (SD)

Disclosures. **All authors:** No reported disclosures.

1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine
Ingrid L. Scully, PhD[1]; Mark W. Cutler, PhD[2]; Seema Gangolli, MS[1]; Todd Belanger, MS[1]; David Cooper, PhD[2]; Thomas Jones, PhD[1]; Andrew McKeen, MS[2]; Charles Tan, PhD[2]; Wendy Watson, MD[1]; Annaliesa S. Anderson, PhD[2]; Kathrin U. Jansen, PhD[2]; Michael W. Pride, PhD[2]; [1]Pfizer Vaccine Research and Development, Pearl River, New York; [2]Pfizer, Inc., Pearl River, New York

Background. Opsonophagocytic assays (OPAs) are an important tool for assessing vaccine-induced functional antibody responses. OPAs are complex assays composed of many biological components (eg serum, complement sources, bacteria, and human phagocytes) which contribute to assay variability and may result in titer drift if not carefully controlled. Rigorous development and validation coupled with routine monitoring of assay performance are required to ensure that high-quality OPA serological data are consistently generated throughout the lifetime of existing and next-generation pneumococcal vaccines.

Methods. OPA specificity was demonstrated by competing functional antibody activity with pneumococcal polysaccharides. Assay qualification/validation assessed accuracy, precision, and sample linearity. Assay performance over time was assessed through the implementation of quality control serum data tracking systems and longterm serum proficiency panels that are routinely tested during assay performance. Human quality control sera are included on each assay plate to ensure that each plate meets pre-specified acceptance criteria. Proficiency serum panels are comprised of individual human serum samples derived from subjects immunized with pneumococcal vaccines and are used to monitor performance across a range of serological titers and over time.

Results. The OPAs were shown to be specific and reproducible. Monitoring of assay performance over time demonstrated that the assays are stable. For the 13 serotypes contained in 13vPnC reliable titers have been generated in over a decade of testing which is an essential prerequisite in the evaluation of next-generation

pneumococcal conjugate vaccines such as 20vPnC, whose licensure depends on demonstration of non-inferiority to 13vPnC.

Conclusion. Maintenance and careful monitoring of high-quality assays to measure functional antibody responses, such as OPAs, is critical for the delivery of reliable serological data to support the advancement of pneumococcal vaccine programs. Pneumococcal OPAs must be rigorously maintained to ensure continuity of serological data over time and inform licensure decisions of next-generation vaccines as well as postmarketing and seroepidemiology studies.

Disclosures. **All authors:** No reported disclosures.

1338. Development of a Novel Application for Differential Diagnosis of Tick-borne Diseases
Corey Meyer, PhD; Jaleal Sanjak, PhD; Audrey Cerles; Christian Garnier; Laurel MacMillan, MS; Gryphon Scientific, Takoma Park, Maryland

Background. Early diagnosis and treatment of tick-borne diseases (TBDs) is critical for mitigating their adverse health outcomes, but the differential diagnosis of TBDs is challenging because many symptoms are nonspecific and commonly used diagnostic assays have significant shortcomings. Furthermore, although the local incidence of TBDs is recognized as an important factor in diagnosis, tools to help clinicians formally consider surveillance data in their decision-making are not available. To address these gaps, Gryphon Scientific developed a differential diagnosis application (app) for TBDs that calculates a patient's likelihood of infection with specific TBDs based on their symptoms, risk factors, and state of suspected tick exposure.

Methods. A differential diagnosis model for TBDs was developed using data on: (1) TBD symptom and risk factor prevalence in TBD patient populations, collected from clinical studies; and (2) human TBD incidence data from notifiable disease surveillance systems and tick infection prevalence data from reports and public databases, which were combined to develop an environmental risk measure. These data were used to build a Bayesian Belief Network (BBN) model that predicts TBD infection probabilities based on a patient's symptoms, risk factors, and state of suspected tick exposure. Performance of the model was validated using case studies from the biomedical literature. The model was incorporated into an app developed in R-shiny, called TBD-DDx (Figures 1 and 3).

Results. A pilot application was developed that includes 10 states (AR, CT, MA, ME, MN, MO, NH, RI, VT, and WI) and the 11 TBDs endemic to those states. The differential diagnosis model identified the patient's true disease as the top-predicted disease in 56% of cases and within the top three predicted TBD in 84% of cases. The inclusion of incidence factors in the model improved performance (Figure 4).

Conclusion. These results demonstrate that the TBD-DDx app is a promising tool for informing clinical diagnoses of TBDs to guide selection of diagnostic testing and treatment. This study represents the first use of a BBN modeling approach that incorporates an environmental risk measure and could be adapted for differential diagnosis of other diseases with environmental or other exposure risks.

TBD-DDx App Inputs: Patient Risk Factor and Location Selection Screen

TBD-DDx App Inputs: Example Patient Symptom Selection Screen